阿佐拉米德通过上调ER陪伴者BiP表达的调节来防止MPP+诱导的多巴氨基神经元死亡
Nana Ai1, Danni Wang2, Shuhui Qu2
1Department of Biomedical Sciences and Centre of Reproduction, Development and Aging (CRDA), University of Macau, Taipa, Macau.
Free radical biology & medicine
|August 25, 2023
概括
阿佐拉米德是一种针对ER压力的化合物,可以防止帕金森病模型. 它通过对BiP进行上调调节来防止多巴氨基神经元死亡,从而提供潜在的神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 帕金森病 (PD) 的特征是渐进的多巴胺基 (DA) 神经元死亡.
- 开发药物来预防DA神经元死亡对于治疗PD至关重要.
研究的目的:
- 调查阿佐拉米德对MPTP诱导的神经退行症的神经保护潜力.
- 阐明阿佐拉米德神经保护作用背后的机制.
主要方法:
- 使用了暴露于神经毒素MPTP的斑马鱼幼虫和SH-SY5Y细胞.
- 评估了细胞活力,核形态,线粒体膜潜力,反应性氧物种和亡生物标志物.
- 研究了ER伴侣BiP及其抑制剂HA15.5的作用.
主要成果:
- 在斑马鱼中,阿佐拉米德预治疗保护了MPTP诱导的DA神经元死亡和运动器官缺陷.
- 在SH-SY5Y细胞中,阿佐拉米德减弱了MPTP诱导的细胞死亡,通过使细胞和亡标记正常化.
- 阿佐拉米德增加了BiP的表达,其保护作用被一个BiP抑制剂阻断.
结论:
- 阿佐拉米德显示出对MPTP诱导的神经毒性的神经保护性.
- 该机制涉及对ER陪伴者BiP的上调,这表明它在缓解ER与压力相关的神经元死亡方面发挥了作用.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Anticholinesterase Agents: Poisoning and Treatment
920
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
920
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Export of Misfolded Proteins out of the ER
3.7K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.7K


